ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
Hagens Berman Sobol Shapiro LLP alerts investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to the firm's investigation into possible securities law violations.
If you purchased or otherwise acquired securities of ACAD before July 9, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more infomation contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing ACAD@hbsslaw.com.
On July 9, 2018, the Southern Investigative Reporting Foundation published a report concluding that ACADIA improperly promoted the faulty illusion that the Company’s core product received FDA approval like any other drug.
This report drove the price of ACADIA shares down $1.21, or almost 7%, to close at $16.63 that day.
“We’re focused on investors’ losses and on the Foundation’s accusations which, if true, could mean ACADIA and senior management misled investors,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding ACADIA should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email ACAD@hbsslaw.com.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.